Active — Not RecruitingNot Applicable

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

United States65 participantsStarted 2022-12-12

Plain-language summary

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
. ER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapy
. Measurable and/or non-measurable disease is allowed
. Male or female breast cancer is allowed
. Age \> 18 years
. Willingness to provide mandatory blood specimens
. Willing to return to enrolling institution for follow up imaging at least once

Exclusion criteria

. Life expectancy of ≤ 6 months
. Inability to provide blood samples based on the judgment of the treating provider

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

To prospectively evaluate the impact of CellSearch CTCs on treatment decisions and response assessment in MBC patients

Timeframe: 3 to 4 months

Trial details

NCT IDNCT05662345

SponsorMenarini Silicon Biosystems, INC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-11-14

View on ClinicalTrials.gov More Metastatic Breast Cancer trials